Biotech · Private company
Repertoire Immune Medicines
Track this companyFree. Adds Repertoire Immune Medicines to your Dealase workspace and tells you when its record changes.
Clinical trials41 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- PD-1 / PD-L1 monoclonal antibodyPhase 2 · Advanced Malignant Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- RPTR-1-201Phase 2 · Advanced Malignant Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- Arm A: RPTR-147:1Phase 1 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- Arm B: RPTR-147:1 and PembrolizumabPhase 1 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- Arm C: RPTR-147:2Phase 1 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- RPTR-168Phase 1 · Head and Neck Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- Tumor ProfilingHead and Neck CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- An Early Phase Trial of RPTR-1-201 in Advanced Solid TumorsPHASE1_PHASE2 · RECRUITING · started Dec 12, 2025ClinicalTrials.gov NCT07293754 · fetched Nov 12, 2026
- RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and MelanomaPHASE1 · TERMINATED · started May 10, 2021ClinicalTrials.gov NCT04762225 · fetched Nov 12, 2026
- This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.TERMINATED · started May 5, 2021ClinicalTrials.gov NCT05061940 · fetched Nov 12, 2026
- RPTR-147 in Patients With Selected Solid Tumors and LymphomasPHASE1 · TERMINATED · started Oct 24, 2018ClinicalTrials.gov NCT03815682 · fetched Nov 12, 2026